Yongan Pharmaceutical: No Apparent Growth Found in Taurine
date：2015-04-10
browse：（897）
Keyword：
On April 8, the Performance Presentation of Yongan Pharmaceutical(002365) 2014 was held on www.p5w.net. Senior management of the company stated in the meeting that since the economy in Europe recovered slowly, the demand of taurine would have no apparent growth and would depend on the market development. Founded in 2001 with a registered capital of RMB187 million, Yongan Pharmaceutical(002365) is a national hi-tech enterprise with self-importation. Taurine is the major product of the company. Counting on its self-developed, patented “epoxy ethane process” for production of taurine, the company makes rapid growth in the production scale and market share, accounting for over 60% of domestic total output. It firmly controls over 50% of the international market share as a leader in the industry both at home and abroad.
The latest article
- White Paper on Bone and Joint Health of Chinese Consumers 2020
- Yili Dairy launched high-protein yogurt, focusing on sport people
- Sinopharm Xingsha launched the Japan's Champion probiotics
- China has introduced its first policy to support the industrial hemp industry
- Beyond Meat became the first overseas Artificial Meat company to set up a factory in China
- Nongfu Spring's market value exceeded HK $370 billion on its first day
- German infant nutrition brand Amykon launched two probiotics in China
- The revenue of Besunyoung in the first half year is about 610 million yuan
- Jellly candy and powder included in the health food filing dosage form in China
- H&H Group net profit increased by 9% for the first half of year
